Pediatric Infection and Vaccine

The Korean Society of Pediatric Infectious Diseases (대한소아감염학회)
권호 표지

Adverse Events Following Yellow Fever Vaccination in Korean Children

우리나라 소아에게 황열예방 백신을 투여 후 발생한 부작용에 대한 고찰

  • Lee, Jae Yo (Department of Pediatrics, National Medical Center) ;
  • Kim, Tae Hee (Department of Pediatrics, National Medical Center) ;
  • Park, Hyang Mi (Department of Pediatrics, National Medical Center) ;
  • Shin, Hye Jung (Department of Pediatrics, National Medical Center) ;
  • Kim, Kyeung Eun (Department of Pediatrics, National Medical Center) ;
  • Lee, Sang Taek (Department of Pediatrics, National Medical Center) ;
  • Kim, Jae Yoon (Department of Pediatrics, National Medical Center)
  • 이재요 (국립의료원 소아청소년과) ;
  • 김태희 (국립의료원 소아청소년과) ;
  • 박향미 (국립의료원 소아청소년과) ;
  • 신혜정 (국립의료원 소아청소년과) ;
  • 김경은 (국립의료원 소아청소년과) ;
  • 이상택 (국립의료원 소아청소년과) ;
  • 김재윤 (국립의료원 소아청소년과)
  • Received : 2008.11.28
  • Accepted : 2009.05.22
  • Published : 2009.06.25
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : Yellow fever, a mosquito-borne viral hemorrhagic fever, is one of the most lethal diseases. Recently there have been an increasing number of Korean children who have travelled to yellow fever endemic zones and were administered yellow fever vaccine (YFV). Therefore, we carried out this study to provide child travelers with safety information of YFV. Methods : This study was conducted at the International Clinic of National Medical Center in Seoul between April 2007 and June 2008 for the evaluation of adverse events of YFV. One hundred twenty-five children received YFV (17-DD) and were prospectively monitored for adverse events through telephone interviews on day 3, 6, 9, 16, 23 and 30 after vaccination. Results : Adverse events were observed in 31 (24.8%) of 125 child travelers who received the YFV. The mean age was 12.5${\pm}$5.0 years. Sixty-six of the child travelers (52.8%) were males. The common adverse events were pain in 11 (8.8%), swelling in 8 (6.4%) and redness in 7 children (5.6%) at the injection site. The systemic adverse events included mild fever in 5 (4.0%), headache in 5 (4.0%), cough in 4 (3.2%), abdominal pain in 3 (2.4%), and vomiting in 2 children (1.6%). Most of the adverse events were detected within 7 days of administration and there were no differences in adverse events by gender or age. All travelers who had complained of symptoms improved spontaneously or following symptomatic treatment. Conclusion : This study showed that YFV is well-tolerated and there were no reports of severe adverse events. Studies are ongoing to clarify the cause and risk factors for rare adverse events.

목 적: 황열은 모기에 의해 전염되는 급성 바이러스 출혈열로 중부아프리카와 열대 남아메리카에서 주로 발생한다. 이 연구는 황열 백신을 접종한 소아 및 청소년 여행객에게 이상반응에 대한 임상적 고찰을 시행하여 백신의 안전성 및 이상반응에 대한 정보를 제공하고자 시행하였다. 방 법: 이 연구에서는 2007년 4월 1일-2008년 6월 30일까지 국립의료원 해외여행클리닉을 방문한 소아 및 청소년 125명을 대상으로 하였다. 황열백신 투여 이후 6회의 전화면담을 통해 백신투여와 이상반응과의 관련성에 대하여 평가하였다. 결 과: 황열백신을 투여한 11개월에서 19세 사이의 소아 및 청소년 125명 중 이상반응의 발생은 31명(24.8 %)이었다. 증상으로는 주사부위의 통증(8.8%)이 가장 많았고 뒤를 이어 부종(6.4%), 발적(5.6%), 발열(4.0%), 두통(4.0%)순서였다. 대부분의 이상반응은 백신 투여 후 7일 이내에 발생했으며 성별 및 연령과 이상반응간의 유의한 차이가 없었다. 증상을 호소한 모두 자연적으로 혹은 보존적인 치료에 증상이 호전되었다. 결 론: 이 연구에서 황열백신은 우리나라 소아나 청소년에게 심각한 이상반응 없이 널리 사용될 수 있음을 보여주었다. 그러나 심각한 부작용의 원인이나 위험요소에 대한 연구는 지속적으로 필요할 것이다.

Keywords

References

  1. Thompson MJ. Immunizations for international travel. Prim Care 2002;29:787-814. https://doi.org/10.1016/S0095-4543(02)00038-6
  2. Mutebi JP, Barrett AD. The epidemiology of yellow fever in Africa. Microbes Infect 2002;4:1459-68. https://doi.org/10.1016/S1286-4579(02)00028-X
  3. Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002; 34:1369-78. https://doi.org/10.1086/340104
  4. Martin M, Tsai TF, Cropp B, Chang GJ, Holmes DA, Tseng J, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001;358:98-104. https://doi.org/10.1016/S0140-6736(01)05327-2
  5. Post PR, de Carvalho R, da Silva Freire M, Galler R. The early use of yellow fever virus strain 17D for vaccine production in Brazil-a Review. Memorias Instituto Oswaldo Cruz 2001;96:849-57. https://doi.org/10.1590/S0074-02762001000600019
  6. Filippis AM, Nogueira RM, Jabor AV, Schatzmayr HG, Oliveira JC, Dinis SC, et al. Isolation and characterization of wild type yellow fever virus in cases temporally associated with 17DD vaccination during an outbreak of yellow fever in Brazil. Vaccine 2004;22:1073-8. https://doi.org/10.1016/j.vaccine.2003.11.002
  7. Monath TP. Yellow fever. In: Plotkin SA, Orenstein WA, Paul A, editors. Vaccines. 5th ed. Philadelphia: Elsevier, Inc, 2008:959-1055.
  8. Sood SK. Immunization for children traveling abroad. Pediatr Clin North Am 2000;47:435-48. https://doi.org/10.1016/S0031-3955(05)70216-9
  9. Monath TP. Yellow fever: an update. Lancet Infect Dis 2001;1:11-20. https://doi.org/10.1016/S1473-3099(01)00016-0
  10. Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis 2007;44:850-6. https://doi.org/10.1086/511869
  11. Barrett AD, Higgs S. Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol 2007;52:209-29. https://doi.org/10.1146/annurev.ento.52.110405.091454
  12. Centron MS, Marfin AA, Julian KG, Gubler DJ, Sharp DJ, Barwick RS, et al. Yellow fever vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 2002;51: 1-11.
  13. Spira A. Yellow fever vaccine as a vehicle to better travel medicine. J Travel Med 2005;12:303-5. https://doi.org/10.2310/7060.2005.12601
  14. Fitzner J, Coulibaly D, Kouadio DE, Yavo JC, Loukou YG, Koudou PO, et al. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast. Vaccine 2004;23:156-62. https://doi.org/10.1016/j.vaccine.2004.05.018
  15. Jong EC, Kaplan KM, Eves KA, Taddeo CA, Lakkis HD, Kuter BJ. An open randomized study of inactivated hepatitis A vaccine administered concomitantly with typhoid fever and yellow fever vaccines. J Travel Med 2002;9:66-70. https://doi.org/10.2310/7060.2002.21955
  16. CDC. Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996-2001. MMWR Morb Mortal Wkly Rep 2001;50: 643-5.
  17. Pugachev KV, Guirakhoo F, Monath TP. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis 2005;18:387-94. https://doi.org/10.1097/01.qco.0000178823.28585.ad
  18. Lang J, Zuckerman J, Clarke P, Barrett P, Kirkpatrick C, Blondeau C. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am J Trop Med Hyg 1999;60:1045-50. https://doi.org/10.4269/ajtmh.1999.60.1045
  19. Collaborative Group for Studies with Yellow Fever Vaccine. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children : Implications for the Brazilian National Immunization Program. Vaccine 2007;25:3118-23. https://doi.org/10.1016/j.vaccine.2007.01.053
  20. Martins MA, Silva ML, Marciano AP, Peruhype- Magalhes V, Eloi-Santos SM, Ribeiro GL, et al. Activation/ modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse events following immunization? Clin Exp Immunol 2007;148:90-100. https://doi.org/10.1111/j.1365-2249.2006.03317.x
  21. Camacho LA, Freire Mda S, Leal Mda L, Aguiar SG, Nascimento JP, Iguchi T, et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica 2004;38:671-8. https://doi.org/10.1590/S0034-89102004000500009
  22. Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VL, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001;358:91-7. https://doi.org/10.1016/S0140-6736(01)05326-0
  23. Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001;358:121-2. https://doi.org/10.1016/S0140-6736(01)05341-7
  24. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 2004;22:2103-5. https://doi.org/10.1016/j.vaccine.2004.01.026
  25. Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005;23:3256-63. https://doi.org/10.1016/j.vaccine.2005.01.089
  26. CDC. Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2002;51:989-93.
  27. Marfin AA, Eidex RS, Kozarsky PE, Cetron MS. Yellow fever and japanese encephalitis vaccines: indications and complications. Infect Dis Clin North Am 2005;19: 151-68. https://doi.org/10.1016/j.idc.2004.11.004
  28. Arya SC. Yellow fever vaccine safety: a reality or a myth? Vaccine 2002;20:3627-8. https://doi.org/10.1016/S0264-410X(02)00409-7
  29. Monath TP, Cetron MS, McCarthy K, Nichols R, Archambault WT, Weld L, et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 2005;1:207-14.
  30. Engel AR, Vasconcelos PF, McArthur MA, Barrett AD. Charaterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine 2006;24:2803-9. https://doi.org/10.1016/j.vaccine.2006.01.009
  31. McGovern LM, Boyce TG, Fischer PR. Congenital infections associated with international travel during pregnancy. J Travel Med 2007;14:117-28. https://doi.org/10.1111/j.1708-8305.2006.00093.x
  32. Osei-Kwasi M, Dunyo SK, Koram KA, Afari EA, Odoom JK, Nkrumah FK. Antibody response to 17D yellow fever vaccine in Ghanaian infants. Bull World Health Organ 2001;79:1056-9.
  33. Rabello A, Orsini M, Disch J, Marcial T, Leal Md Mda L, Freire Md Mda S, et al. Low frequency of side effects following an incidental 25 times concentrated does of yellow fever vaccine. Rev Soc Bras Med Trop 2002; 35:177-80. https://doi.org/10.1590/S0037-86822002000200008
  34. Choudri Y, Walop W. Review of adverse events reported following use of fever vaccine-Canada, 1987-2000. Can Commun Dis Rep 2002;28:9-15.
  35. Robertson S. Yellow fever: the immunological basis for immunization. Document WHO/EPI/GEN/93. 181993.